AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

Core Insights - AnaptysBio, Inc. announced that investigational ANB032 did not meet primary and secondary endpoints in the ARISE-AD trial for moderate-to-severe atopic dermatitis [1][4] - The company will discontinue further investment in ANB032 and focus on its autoimmune portfolio [2] - ANB032 was well tolerated with no safety signals observed across all doses [6] Study Details - The ARISE-AD trial enrolled 201 patients with a mean baseline EASI score of 27.3, including both biologics naïve and experienced patients [2] - Patients were randomized to receive different dosing regimens of ANB032 or placebo for 12 weeks [3] - The primary endpoint was not met, with no significant improvement in EASI-75 or other secondary endpoints at Week 14 [4] Efficacy Observations - Absolute response rates approached the minimum target product profile, but higher placebo response rates were noted, particularly in the U.S. [5] - Despite the lack of efficacy, ANB032 was reported to be safe and well tolerated [6] Market Reaction - Following the announcement, AnaptysBio's stock price fell by 36.3%, trading at $14.72 [7]